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A B S T R A C T
Non-Hodgkin lymphoma is the fourth most common malignancy in children, has an even higher
incidence in adolescents, and is primarily represented by only a few histologic subtypes. Dramatic
progress has been achieved, with survival rates exceeding 80%, in large part because of a better
understanding of the biology of the different subtypes and national and international collaborations.
Most patients with Burkitt lymphoma and diffuse large B-cell lymphoma are cured with short intensive
pulse chemotherapy containing cyclophosphamide, cytarabine, and high-dose methotrexate. The
benefit of the addition of rituximab has not been established except in the case of primary mediastinal
B-cell lymphoma. Lymphoblastic lymphoma is treated with intensive, semi-continuous, longer
leukemia-derived protocols. Relapses in B-cell and lymphoblastic lymphomas are rare and infrequently
curable, even with intensive approaches. Event-free survival rates of approximately 75% have been
achieved in anaplastic large-cell lymphomas with various regimens that generally include a short
intensive B-like regimen. Immunity seems to play an important role in prognosis and needs further
exploration to determine its therapeutic application. ALK inhibitor therapeutic approaches are currently
under investigation. For all pediatric lymphomas, the intensity of induction/consolidation therapy correlates
with acute toxicities, but because of low cumulative doses of anthracyclines and alkylating agents, minimal
or no long-term toxicity is expected. Challenges that remain include defining the value of prognostic factors,
such as early response on positron emission tomography/computed tomography and minimal dissemi-
nated and residual disease, using new biologic technologies to improve risk stratification, and developing
innovative therapies, both in the first-line setting and for relapse.
J Clin Oncol 33:2963-2974. © 2015 by American Society of Clinical Oncology
INTRODUCTION
Non-Hodgkin lymphoma (NHL) is a heteroge-
neous group of lymphoid malignancies. The histo-
logic classification of these diseases has changed
many timesover the years as a result of better under-
standing of lymphomagenesis and development of
new diagnostic tools. The 2008 WHO classification
of lymphoma is now widely used, providing
clinicians with a common language and valuable
comparisons.1 NHL is the fourth most common
malignancy across the pediatric age spectrum. Pedi-
atric NHL exhibits significant differences in the dis-
tribution of histologic subtypes toNHL observed in
adults with clinical features characterized by almost
exclusively diffuse high-grade lymphomas and fre-
quent extranodal involvement. Dramatic progress
has been achieved indeveloping curative therapy for
pediatric NHL, with an overall survival rate now
exceeding 80%.Because of the relatively small num-
bers of each subtype, such progress could not have
been achieved without national and international
collaborations especially through the European In-
tergroup for Childhood NHL (EICNHL), which
comprises most European countries, Japan and
Hong Kong, and the North American Children’s
Oncology Group (COG). This review will present
current knowledge on pediatric NHL and identify
future research directions, especially in terms of bi-
ology and new therapies.
GENERALITIES
Epidemiology and Histopathology
The overall incidence and frequency of the dif-
ferent histologic subgroups of NHL vary according
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to age at diagnosis. Data from the US National Cancer Institute’s
Surveillance, Epidemiology, and End Results program have demon-
strated a steady increase in NHL with age. The annual incidence per
million inhabitants ranges from5.9 inchildrenyounger than5yearsof
age to about 10 in children between 5 and 14 years old, and 15 in
adolescents (approximately 150 in adults).2 The increased incidence
in adolescents is related to the higher incidence of large-cell lympho-
mas at that age. The vast majority of childhood NHL is high-grade
lymphoma,mostly of B-cell origin (Table 1).1,3,4Other subtypes, such
as peripheral T-cell lymphoma, extranodal natural killer/T–cell lym-
phoma, and follicular lymphoma, represent less than 5% of all pedi-
atric NHL.
It is well known that immunodeficiency, either primary (such as
ataxia telangiectasia or Nijmegen breakage syndrome) or secondary
(induced by HIV or immunosuppressive drugs), increases the risk of
NHL.5,6Lessknownandmorerecentlydescribedare theassociationof
interleukin (IL) -10 receptor deficiency with childhood B-cell NHL
(B-NHL)7 and the increased risk of NHL in the constitutional mis-
match repair deficiency syndrome. The latter is characterized by bial-
lelic germline mutations of mismatch repair genes and multiple
cancers including NHL, brain tumors, and colorectal cancers in chil-
dren with café au lait spots.8
Staging
The Ann Arbor classification is not adapted to childhood NHL
because of its predominant involvement in extranodal primary sites.
The commonly used St Jude staging classification designates medias-
tinal and extensive abdominal lesions as stage III and restricts stage IV
assignment tobonemarrow(BM)andCNS involvement regardless of
involvement of other visceral sites. The International Prognostic In-
dex is not used in childhoodNHL because of the difference in staging
and because the performance status index does not reflect quality-of-
life deterioration but rather rapidity of tumor growth and tumor
volume. The role of fluorodeoxyglucose (FDG) positron emission
tomography (PET)/computed tomography (CT) in themanagement
of childhood NHL has yet to be established. PET-FDGmay be more
accurate than conventional imaging to assess disease involvement
becausehighFDGuptakehasbeen shown inmost subtypes (Abbouet
al, submitted for publication), but its impact on therapeutic stratifica-
tionhasnot been evaluated.The role of FDG-PET in remission assess-
ment has only been investigated in small series. Most reports indicate
high rates of false-positive results, requiring histologic examination of
residual masses before treatment modification (Abbou et al, submit-
ted for publication). Lastly, the prognostic value of early (after one to
three cycles of chemotherapy) FDG-PET/CT response assessment has
Table 1. Immunophenotypic, Cytogenetic, and Molecular Markers of Pediatric NHL
Marker
Histology and Frequency
BL (50%-60%)
LBCL (10%-15%) LL (20%-25%)
ALCL (10%-12%)DLBCL PMBL B-LL T-LL
Immunohistochemistry
MIB1 100% 40%-90% 30%-90% Not informative Not informative Not informative
CD10  / / / / 
CD19      
CD20    /  
CD79a      
sIg  /    
Bcl-6  / /   /
MUM1  /    
MAL  /    
TdT      
cCD3      /
CD4     / /
CD8     / /
CD7      /
CD5  /   / /
CD30  † /   
ALK  ‡    
Cytogenetic t(8;14)(q24;q32)
t(2;8)(p12;q24)
t(8;22)(q24;q11)
R8q24 (30%) Few data Few data Translocations involving
14q11-13; few other
data
t(2;5)(p23;q35)  90%
or variants involving
2p23
Molecular biology MYC/IGH
IGK/MYC
MYC/IGL
Nuclear factor-B
pathway
dysregulation
IGH/TCR
rearrangements
NOTCH/FBXW7,
PTEN
IGH/TCR rearrangements
NPM/ALK  90% or
variants
NOTE. Other NHLs, such as peripheral T-cell lymphoma, extranodal natural killer/T–cell lymphoma, nasal type, and pediatric follicular lymphoma, represent less than
5% of pediatric NHLs and are not indicated in the table.
Abbreviations: ALCL, anaplastic large-cell lymphoma, ALK positive; BL, Burkitt lymphoma; B-LL, B-cell lymphoblastic lymphoma; DLBCL, diffuse large B-cell
lymphoma; LBCL, large B-cell lymphoma; NHL, non-Hodgkin lymphoma; PMBL, primary mediastinal (thymic) large B-cell lymphoma; T-LL, T-cell
lymphoblastic lymphoma.
,  90% of patients; /,  50% of patients; /,  50% of patients; ,  10% of patients.
†Positive especially in the rare anaplastic variant.
‡Positive in the ALK-positive LBCL.
Minard-Colin et al
2964 © 2015 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
147.162.241.198
Information downloaded from jco.ascopubs.org and provided by at Universita Studi di Padova on June 8, 2016 from
Copyright © 2015 American Society of Clinical Oncology. All rights reserved.
also not been established. A prospective study is ongoing in France
since 2011 for B-NHL, lymphoblastic lymphoma (LL), and anaplastic
large-cell lymphoma (ALCL) to evaluate the role of FDG-PET/CT in
pediatric NHL (ID-RCB: 2010-A01154-35).
Several groups have investigated the prognostic impact of mini-
mal disseminated disease (MDD) at diagnosis identified bymolecular
techniques or flow cytometry in the blood, BM, and/or CNS.9-11
Recently, amultidisciplinarymultinational group proposed aRevised
International Pediatric NHL Staging System Classification and Inter-
national Pediatric Non-Hodgkin lymphoma Response Criteria for
improved staging and response assessments.11a,11b
Treatment
At the beginning of the 1980s, investigators contended that the
type ofmultiagent chemotherapy should differ according to theNHL
histology based on clinical experiences. A Children’s Cancer Group
randomized study showing that LL benefited from a 10-drug
leukemia-like LSA2L2 protocol and that non-LL had better outcomes
with a four-drug cyclophosphamide, vincristine, methotrexate
(MTX), and prednisone regimen confirmed these perceptions.12
Since 1981, national groups have conducted prospective trials with
different strategies, including essential CNS prophylaxis, for B-NHL
and LL that significantly advanced cure rates in these diseases.
MATURE B-CELL LYMPHOMA
Burkitt lymphoma (BL) accounts for more than 80% of childhood
B-NHL. It generally arises in the abdomen and/or head and neck
region and presents as advanced-stage disease involving the BM
and/orCNS inapproximately20%to25%ofpatients.Outcomeshave
improved dramatically as a result of several consecutive prospective
trials, such as the French Society of Pediatric Oncology and French-
American-British (FAB) LymphomesMalins B (LMB) and the oligo-
national Berlin-Frankfurt-Munster (BFM) studies (Table 2).4,13-20
Treatment of BL is based on 2 to 6months of intensive pulse polyche-
motherapy. Relapses occur early, typically within the first year. The
LMBstudies,13,14 including the international FAB/LMB96 trial,15-17,21
sequentially demonstrated that high-dose (HD) MTX is an effective
drug forCNSprophylaxis; patientswithmature B-cell acute leukemia
and CNS-positive disease benefit from a higher dose of HDMTX and
the addition of HD cytarabine (Ara-C [in cytarabine/etoposide
(CYVE) courses]); treatment intensity should be based on tumor
resectability, stage, and response to chemotherapy (at day 7 and after
three courses); early dose-intensity is essential as evident by a 10%
lower event-free survival (EFS) in the intermediate-risk group of the
FAB/LMB96 trial when the second induction course started later than
21days after thefirst one; and the total dose of cyclophosphamide and
doxorubicin could be reduced to 3.3 g/m2 and 120 mg/m2, respec-
tively, formore than70%ofpatients, substantially reducing the risk of
gonadal andcardiac toxicity.TheBFMstudies4,18,19 showed that treat-
ment intensity can be adapted to the lactate dehydrogenase (LDH)
level; HDMTX is an effective systemic drug; and advanced disease
benefits from more prolonged HDMTX exposure and HDAra-C.
Although stratification and the therapy intensity are not exactly com-
parable in the LMB and BFM strategies, the results are quite similar.
Other studies also showed the value of short-duration therapy and
confirmed that cyclophosphamide, HDMTX, and Ara-C are the ma-
jordrugs inBL, in addition to vincristine, doxorubicin, etoposide, and
corticosteroids.20 Collectively, all studies established the effectiveness
of CNS prophylaxis with HDMTXHDAra-C and intrathecal (IT)
injections of MTX Ara-C, eliminating the need for cranial irradia-
tion. In higher income countries, the EFS of BL reaches 80% to 90%
using these strategies; however, acute treatment-related toxicities ne-
cessitate adequate supportive care and protocol management experi-
ence (Table 2).15-17,19-21
BL frequently occurs in countrieswith fewer resources, especially
in sub-Saharan countries. Treatment should be adapted to find a
compromise between sufficient effectiveness, tolerable toxicity, and
socioeconomic constraints. Several groups have published results
demonstrating cure in about half of the children with resource-
adapted protocols.22,23 These cure rates should improve with experi-
ence, better resources, and less family abandonment of treatment.
Diffuse large B-cell lymphoma (DLBCL) accounts for 10% to
20% of B-cell lymphoma in children and occurs more frequently in
adolescents.24 DLBCL in children is more homogeneous than in
adults, with themajority originating from germinal centers (germinal
center B-cell–like [GCB]), possibly representing a distinct biologic
subgroup of GCB devoid of BCL6/3q27 and BCL2/18q21 transloca-
tions.25,26 MYC/8q24 is frequently rearranged (20% to 30%), in con-
trast to adult DLBCL (5% to 10%).27 Outcomes in children and
adolescents are similar to those ofBLwith the sameprotocols except that
relapses have been reported up to 3 years after diagnosis.14,18,20
The subgroup of primary mediastinal large B-cell lymphoma
(PMBL) has to be distinguished from other DLBCL.19,27,28 Using BL
pediatric protocols, EFS is lower than inDLBCL (70%), but similar to
that obtained with adult protocols. PMBL biology is similar in both
age groups (although gray zone lymphomawith features intermediate
between DLBCL and classical Hodgkin lymphoma is infrequently
seen in children),29 suggesting that rituximab-containing treatment
regimens may improve outcomes as seen in adults.
The use of rituximab in pediatric B-NHL remains a relevant
clinical question. Pilot studies have yielded responses for single-drug
use in newly diagnosed BL30 and immediate good tolerance when
combined with induction chemotherapy.31,32 However, considering
the high cure rates obtained in children and adolescents with antici-
pated no or minimal long-term toxicity, the benefit of adding ritux-
imab to conventional chemotherapy in BL has yet to be established.
The ongoing Inter-B-NHL Ritux 2010 international trial combines a
randomized phase III study testing the impact of adding rituximab to
the LMB regimen for advanced-stage B-cell lymphoma and a phase II
study of the dose-adjusted etoposide, prednisone, vincristine, cyclo-
phosphamide, doxorubicin, and rituximab regimen for PMBL33
(ClinicalTrials.gov identifier: NCT01516580; Table 2).
Clinical prognostic factors observed in previous B-NHL studies
include stage; LDH level; CNS involvement, especially the presence of
blasts in the cerebrospinal fluid; and treatment-related factors such as
early response, initial dose-intensity, and complete response (CR).
Biologic characteristics also seem to have prognostic value, including
the presence of 13q abnormalities, MYC/8q24 rearrangement in
DLBCL, andMDD andminimal residual disease (MRD) in BL.9,27,34
These results require confirmation in larger prospective studies, as
planned in the Inter-B-NHL Ritux 2010 study.
Relapses in B-NHL are rare, but their outcome is dismal, with a
cure rate of less than 30%.35-37 CYVE38 and rituximab, ifosfamide,
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carboplatin, and etoposide39 regimens are effective reinduction che-
motherapy in achieving a second CR, with CR rates of 45%37,38 and
35%,39 respectively. HD chemotherapy and hematopoietic cell sup-
port are needed to consolidate the second CR. An allograft does not
afford more benefit than an autograft,40 but the former could be
considered to maintain dose-intensity and/or in case of leukemic
involvement. Adverse prognostic factors at relapse include early re-
lapse (within 6 months), multiple sites of recurrence, BL histology,
and initial presentation features (eg, elevated LDH and advanced-
stage disease).35-37
Innovative therapies are difficult to explore in childhoodB-NHL
because of the small number of patients with refractory/relapsed dis-
ease. The most promising therapies include new antibody therapies
alongwith immunomodulatory agents that improve antibody-coated
tumor cell killing andBruton’s tyrosine kinase inhibitors.Newmono-
clonal antibodies targeting B-cell markers such as next-generation
humanized anti-CD20, obinutuzumab (GA101), or veltuzumab
(IMMU-106) may be active, but none have been investigated in re-
lapsed/refractory childhood B-NHL. Other new agents include the
bi-specificCD20/CD22 orCD20/CD74 antibodies and the bi-specific
CD19/CD3T-cell engagerblinatumomab(AMG103),witha reported
response rate of approximately 55% among adults with relapsed ag-
gressive B-NHL.41 Another promising agent is ibrutinib, a potent oral
inhibitor of Bruton’s tyrosine kinase, which has a direct effect on
malignant B cells and may also regulate the tumor B-cell microenvi-
ronment. Ibrutinib has demonstrated single-drug activity in relapsed/
refractoryB-cellmalignancies in adults andhas recentlybeen reported
to have a favorable tolerance profile and efficacywhen combinedwith
rituximab, cyclophosphamide, doxorubicin, vincristine, and predni-
sone in a nonrandomized study of newly diagnosed adult DLBCL
(mostly post–germinal center disease).42Thus, ibrutinib could be a
novel targeted therapy for relapsed/refractory childhood B-NHL in
combination with a chemo-immunotherapy backbone.
Technologies such as next-generation sequencing, microRNA
and gene expression profiling, and single nucleotide polymorphism
array analysis may identify novel therapeutic targets. In BL, genetic
alterations other than the 8q24/MYC translocation participate in the
deregulation of the MYC pathway and may be essential for disease
initiation and progression. Recurrentmutations in the PI3K pathway
suggest a cooperative role betweenMYC overexpression and deregu-
lation of PI3K signaling.43 Other studies highlight the pathogenic and
clinical relevance ofmutations affecting the transcription factorTCF3
(E2A) or its negative regulator ID3, a novel tumor suppressor gene,
withTCF3 or ID3mutations affecting nearly 70%of sporadic BL.44-46
Inaddition,mutations ingenes includingCCND3,GNA13,TP53, and
SMARCA4 have been described. Interestingly, a comparison between
the frequency of mutations in BL and adult GCB DLBCL revealed a
stronger overlap, further supporting the notion that BL and GCB
DLBCL both originate from germinal center B cells.47 Altogether,
these findings support the development of drugs targeting the PI3K
kinase pathway, antigen-independent BCR signaling, and cyclin D3/
CDK6 pathways in relapsed/refractory childhood B-NHL.
LL
LL includes both precursor T-cell (T-LL) and B-cell (B-LL) NHL.
Unlike acute lymphoblastic leukemia (ALL),with predominant B-cell
diseases, most LL is of T-cell origin, rather than B-cell origin (80% to
90% v 10% to 20%, respectively). T-LL generally presents withmedi-
astinal and advanced-stage disease (stage III or IV in  90% of pa-
tients) andmay involve BM (approximately 30%) and less often CNS
(approximately 5%) at diagnosis. B-LL is more likely to involve the
skin, soft tissue, bone, and peripheral lymph nodes and represents the
majority of the localized stages.48
Both precursor B- and T-lymphoid blasts usually express ter-
minal deoxynucleotidyl transferase (TdT). TdT expression is the
best immunohistochemical marker for determining the precursor
origin of the neoplasm.49 This is useful for differentiating B-LL
frommature B-NHL, because they can express other similarmark-
ers (CD79a, CD10, and CD19 and/or CD20; Table 1).
The best treatment approaches for childhood advanced LL are
ALL-based therapeutic regimens (eg, LSA2L2
50 and BFM4,51,52 regi-
mens). These protocols were modified by adding HDMTX to the
original LSA2L2 protocol to improve CNS prophylaxis
53 and by grad-
ually excluding local and CNS radiotherapy.52,54 Regimens are based
on semi-continuous intensive polychemotherapy followed by main-
tenance therapy for a total duration of 2 years (Table 3).4,11b,52,53,55-63
Numerous drugs are given including corticosteroids, vincristine, an-
thracyclines, cyclophosphamide, Ara-C, asparaginase, andMTX. Sev-
eral studies have demonstrated significance of asparaginase and its
dose-intensity in LL outcomes.62,63 CNS prophylaxis, another impor-
tant component of treatment, generally involves HDMTX and/or IT
injections. The randomized Pediatric Oncology Group56 and COG60
studies investigated the importance of HDMTX in LL. CNS prophy-
laxis with either sufficient number of IT injections or HDMTX pre-
vented CNS relapse. In contrast to BL, these studies suggested that
HDMTX may not have as profound a systemic effect in LL. Other
protocols introduced early intensification to BFM-like regimens to
produce more rapid disease response, but this approach did not im-
prove long-term outcome.60,62
Of note, outcomes for pediatric LL have not changed signifi-
cantly since the 1980s, with most clinical trials achieving EFS rates of
75% to 85% (Table 3). The BFM90 study, which attained a 90% EFS
rate, represents the only exception, but this result was not reproduced
in the subsequent BFM95 study.52 Despite minimal differences be-
tween the two protocols, the divergent results obtained may be ex-
plained by a different dose and type of asparaginase. To date, except
for stage (localized v advanced), no clinical prognostic factors have
been identified.51,64 A trend toward a better prognosis was shown in
patients with a very good response after the 7-day prephase of corti-
costeroids54 or with a radiologic response at 2 weeks.60 The EICNHL
group designed the Euro-LB02 trial to compare dexamethasone
(known to better penetrate the CNS) to prednisone in the induction
phase and evaluate the possibility of decreasing the duration of treat-
ment from 24 to 18months (second random assignment). The refer-
ence arm was the NHL-BFM90 regimen without cranial irradiation,
andonlypatientswithT-LLwere randomlyassigned.The studyhad to
be closed prematurely because of excess toxic deaths. Preliminary
results61 showed anEFS rate of 81% 2% for the 319 eligible patients
(75% T-LL) with a median follow-up of 4.8 years. Although no CNS
relapses occurred in the dexamethasone arm, survival was not better.
Because of relevant acute and long-term toxicity and poor prog-
nosis at relapse, identifying prognostic factors is an important chal-
lenge in LL. This has been hampered by the rarity of the disease and,
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moreover, by difficulties in obtaining appropriatematerial for immu-
nophenotypic and molecular characterization. MDD and MRD can
be studied using polymerase chain reaction (PCR) –based methods,
molecular techniques, or flow cytometry in ALL. MDDmeasured by
flow cytometry in a series of 99 T-LLs was present in two thirds of
patients without cytologic BM involvement.10 Interestingly, therewas
good correlation inpairedBMandblood samples.High level ofMDD
was associated with a higher risk of hematologic relapses but not with
local relapse. Further studies are needed to confirm the possibility of
stratifying treatment on MDD and MRD in LL, as is already being
done in ALL. Several biologic characteristics considered of prognostic
relevance in T-LL have been described; in the BFM series,65 loss of
heterozygosity (LOH) on chromosome 6q (LOH6q; 12%of patients)
was significantly associated with poorer outcome (EFS, 27% 9% v
86% 3% if no LOH6q), whereas the presence of NOTCH1 muta-
tions (60% of patients) was associated with favorable outcome (EFS,
84%  5% v 66%  7% for no NOTCH1 mutations). NOTCH1
mutations andLOH6q16were almostmutually exclusive. In a French
series66 studyingFLASHdeletiononchromosome6q,TCR rearrange-
ments, and NOTCH1/FBXW7 mutations, the latter was the only in-
dependent prognostic factors identified by multivariable analysis
(EFS, 96% 0.04 v 45% 0.13 for presence v absence of mutations;
P  .01). Finally, the prognostic value of RAS/PTEN alteration and
absence of biallelic TCR- deletion also warrants evaluation in T-LL,
by extrapolation from T-cell ALL.
With intensive first-line treatment, refractory disease or relapse
occurs in 10% to 20% of patients. Relapse is mostly local inmediasti-
nal T-LL.Theoutcome is dismal,with a cure rate of generally less than
30%.67-69 In LL, there is a clear indication for an allograft if a second
CR is achieved.40 However, the difficulty of obtaining a second CR
emphasizes the need for new treatments. So far, new agents for T-LL
such as nelarabine69 or clofarabine70 havedemonstrated limited effec-
tiveness. Blinatumomab, a bi-specific CD19/CD3 antibody, may be
promising for B-LL.
ALCL
Two forms of ALCL have been described—systemic and cutaneous
ALCL. Systemic ALCL is characterized by peripheral, mediastinal, or
intra-abdominal lymphnode involvement, frequently associatedwith
“B” symptoms and extranodal disease.A translocation resulting in the
fusionof the anaplastic lymphomakinase (ALK) gene tooneof several
partners can be detected inmore than 90% of patients.
Primary cutaneous ALCLs usually lack ALK translocations and
belong to the spectrum of primary cutaneous CD30-positive lym-
phoproliferative disorders, a group that also includes lymphomatoid
papulosis. These entities remain confined to skin and usually carry an
excellent prognosis after surgical resection without systemic therapy.
ALCLs express CD30 and, in most cases, EMA and cytotoxic
molecules such as TIA-1, granzyme B, or perforin. Most patients
express at least oneT-cell antigen and exhibit clonal rearrangement of
the T-cell receptor. Several histologic subtypes have been described
including the common, small-cell, lymphohistiocytic, Hodgkin-like,
and composite patterns.71 The most common ALK fusion protein is
nucleophosmin (NPM)-ALK resulting from the t(2;5) translocation.
Several other partners can be involved. Most fusion products can be
detected using fluorescent in situ hybridization, reverse transcriptase
PCR, or immunohistochemistry.71 These translocations induce con-
stitutive phosphorylation of ALK that activates multiple pathways
such JAK/STAT3, AKT/PI3K, and RAS/ERK, leading to growth
factor–independent cell proliferation and inhibition of apoptosis.
In previous therapeutic studies with diverse first-line chemo-
therapy regimens in terms of duration of treatment and the num-
ber and cumulative doses of drugs, similar EFS rates of
approximately 65% to 75% have been achieved in children and
adolescents (Table 4).72-79 Most pediatric groups now treat pa-
tients according to the ALCL99 protocol, a chemotherapy regimen
derived from the NHL-BFM-B regimen, with MTX 3 g/m2 in a
3-hour infusion and without IT therapy.73
One of the unique features of ALCL compared with other pedi-
atricNHLis its sensitivity tochemotherapyafter recurrence, leading to
a survival rate of more than 90% in the recent ALCL99 study.73,80-83
Several strategies, including reinduction chemotherapy followed by
autologous or allogeneic hematopoietic stem-cell transplantation or
weekly vinblastine, have been successful. The efficacy of vinblastine,
initially showninasmall seriesofpatientswithmultiple relapses,83was
confirmed in theEuropeanALCLrelapse study.An interimanalysis in
August 2011 showed an 87% 2-year EFS rate in a small series of
Table 4. Results of the Main Series of Pediatric ALCL
Protocol
Study Group and
Period of Study Treatment Strategy
Treatment
Duration
(months)
No. of
Patients
3- to 5-Year
EFS (%)
3- to 5-Year
OS (%)
HM89-9172 SFOP, 1989-1997 B-cell regimen (COPADM  maintenance) 7-8 82 66 83
NHL-BFM9074 BFM, 1990-1995 B-cell regimen (BFM-B) 2-5 89 76 —
NHL 9000 and 960275 UKCCSG, 1990-1998 B-cell regimen (LMB) 4-5 72 59 65
LNH9276 AEIOP, 1993-1997 T-cell regimen 24 34 65 85
POG931578 POG, 1994-2000 APO  randomization of HDMTX and HDAra-C 12 86 72 88
CCG594178 CCG, 1996-2001 Compressed T-cell regimen 11 86 68 80
ALCL9973,80 EICNHL, 1999-2006 B-cell regimen (BFM-B)  randomization of vinblastine 4-12 352 73 92
ANHL013179 COG, 2004-2008 APO  randomization of vinblastine 12 125 74 84
Abbreviations: AEIOP, Italian Association of Pediatric Hematology and Oncology; ALCL, anaplastic large-cell lymphoma; APO, doxorubicin, prednisone, and
vincristine; BFM, Berlin-Frankfurt-Munster; CCG, Children’s Cancer Group; COG, Children’s Oncology Group; COPADM, vincristine, methylprednisolone,
methotrexate, leucovorin, cyclophosphamide, and doxorubicin; EFS, event-free survival; EICNHL, European Intergroup for Childhood Non-Hodgkin Lymphoma;
HDAra-C, high-dose cytarabine; HDMTX, high-dose methotrexate; LMB, Lymphomes Malins B; NHL, non-Hodgkin lymphoma; OS, overall survival; POG, Pediatric
Oncology Group; SFOP, Société Francaise d’Oncologie Pédiatrique; UKCCSG, United Kingdom Children’s Cancer Study Group.
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patients with a late relapse (median follow-up, 34 months) treated
with vinblastine.84 The role of weekly vinblastine maintenance in
first-line treatment has also been investigated in the ALCL99 trial
(addition of vinblastine to each course and as maintenance for a total
treatment duration of 12 months) and in the COG ANHL0131 trial
(vincristine replaced by weekly vinblastine in the doxorubicin, pred-
nisone, and vincristine regimen), but no reduction in risk of relapse
could be demonstrated with this duration of treatment.79,80
Several prognostic factors associated with an increased risk of
failure have been identified in ALCL, including the presence ofmedi-
astinal or visceral involvement and skin lesions,85 histologic lympho-
histiocytic and small-cell variant patterns, and the detection of MDD
by reverse transcriptase PCR for NPM-ALK in blood or BM.(positive
in approximately 50% of patients, whereas 15% of patients exhibit
cytologically detectable BM disease).71,75,76,86,87 More recently, new
parameters such as the persistence of positiveMRD after 4 weeks88 of
treatment and low production of anti-ALK titers were also identified.
In a series of 128 patients, MDD and antibody titer allowed stratifica-
tion into the following three biologic risk groups89: high risk with
MDD-positive status and low antibody titer (20% of patients; 5-year
PFS, 28%), low risk with MDD-negative status and a high antibody
titer (31%ofpatients; 5-yearPFS, 93%), and intermediate risk includ-
ing the remaining patients (48% of patients; 5-year PFS, 68%). Vali-
dation of this prognostic classification is planned in the future
EICNHL clinical study.
Accumulating evidence indicates that the immune system
plays a major role in both the pathogenesis and final control of
ALK-positiveALCL.90 Antibodies against ALK and cytotoxic T-cell
and CD4T-helper responses to ALK have been detected in patients
with ALK-positive ALCL both at diagnosis and during remission,
with a significant inverse correlation between ALK antibody titers
and incidence of relapse.91 The presence of germline monoallelic
mutations of the perforin gene has been demonstrated in ALCL,
suggesting that impairment of cytotoxic lymphocyte functionmay
predispose to ALCL.92
Interestingly, vinblastine is a potent immunomodulator that en-
hances anticancer immune response by stimulating dendritic cell
(DC) function. In vitro, vinblastine induces the production of IL-1,
IL-6, and IL-12; increases surface expression of CD40, CD80, CD86,
and major histocompatibility complex class II; and enhances T-cell
stimulatory capacity of DCs.93 Vinblastine is speculated to release the
highmobility groupbox1protein,94 amajormolecule involved inDC
stimulation and immunogenic cell death.
Several new drugs have recently been implemented in the
treatment of ALCL. Brentuximab vedotin (BV) is an anti-CD30
monoclonal antibody conjugated to the antimicrotubule cytotoxic
monomethyl auristatin-E. A study of 58 patients with relapsed/
refractory ALCL (ALK positive, n 16) treated with BV reported
an objective response rate of 86% with a median duration of 12.6
months.95 After these results, BVwas approved by theUS Food and
Drug Administration and European Medical Agency for the treat-
ment of systemic ALCL after failure of at least one chemotherapy
regimen in adults.
ALK inhibitors such as crizotinib, an ALK/MET inhibitor, are
also promising drugs. Crizotinib is nowapprovedby theUSFood and
DrugAdministrationandEuropeanMedicalAgency for the treatment
of ALK-positive lung cancers. The results in ALCL are also encourag-
ing with seven CRs in nine patients with relapsed/refractory ALCL
included in a pediatric phase I trial of crizotinib.96 The same results
were obtained with a response rate of 91% in 11 patients with ALK-
positive resistant/refractory adult lymphoma.97 Given these results,
the COG is currently investigating the feasibility of combining BV or
crizotinib with ALCL99 chemotherapy in children with newly
diagnosed stage II to IV ALCL (ClinicalTrials.gov identifier:
NCT01979536), whereas the EICNHL is planning a randomized trial
with risk stratification based on MDD and antibody levels, aimed at
evaluating the efficacy of adding crizotinib to ALCL99 in first-line
therapy for intermediate- and high-risk ALCL and comparing weekly
vinblastine to ALCL99 in low- and intermediate-risk disease.
CONCLUSION
Thanks to better recognition of the diseases and to national and
international collaborations, the vastmajority of children and adoles-
cents withNHLwill be cured using chemotherapy adapted to specific
lymphoma subtype anddisease extent.However, contemporary treat-
ments are often associatedwith acutemyelosuppressive andGI toxic-
ities that not only hamper quality of life, but can also be life
threatening.However, formany children, few long-term toxicities are
anticipated because of low cumulative chemotherapy doses and elim-
ination of radiation therapy.
The therapeutic strategies and treatment intensity vary consider-
ably between pediatric and adult approaches for similar NHL sub-
types. The lack of uniform criteria for staging and the limited data
concerning age-related biologic characteristics of each subtype pre-
clude understanding of the impact of these differences on patient
outcomes. Defining new prognostic factors will facilitate the develop-
ment of better risk-adapted strategies. New treatments including an-
tibodies and/or targeted therapies hold promise for advancing
outcomes in children with refractory/relapsed lymphoma. It is im-
probable that theywill cureNHLon their own, but their combination
with chemotherapy may allow reduction in treatment intensity and
chemotherapy-related toxicities. Except for high-risk patients who
require further therapeutic improvements, the challenge over the
coming years will be to maintain already high cure rates while mini-
mizing acute and long-term toxicity. This effort will require further
pediatric international collaboration aswell as partnershipswith adult
lymphoma groups.
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